Precigen Interest Expense 2011-2026 | PGEN

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Precigen

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-	8.53 M	611 K	861 K	1.24 M	666 K	141 K	57 K	183 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
8.53 M	57 K	1.54 M

Quarterly Interest Expense Precigen

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.47 M	4.36 M	4.31 M	-	4 M	142 K	99 K	-	138 K	181 K	179 K	-	227 K	267 K	265 K	-	310 K	359 K	343 K	-	230 K	40 K	39 K	-	6 K	11 K	14 K	-	17 K	18 K	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
4.47 M	6 K	871 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Ascendis Pharma A/S ASND	80.6 M	$ 234.24	-0.3 %	$ 5 B	Danmark
Harmony Biosciences Holdings HRMY	-680 K	$ 27.99	4.17 %	$ 1.59 B	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.33	0.79 %	$ 8.01 B	Australia
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Axsome Therapeutics AXSM	-15.9 M	$ 167.61	-4.09 %	$ 8.34 B	USA
Atreca BCEL	3 K	-	-11.76 %	$ 5.79 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	-12.6 M	-	0.49 %	$ 251 B	Cayman-islands
Biogen BIIB	268 M	$ 194.87	-0.75 %	$ 28.5 B	USA
BioVie BIVI	4.3 M	$ 1.25	0.4 %	$ 1.85 M	USA
Bellicum Pharmaceuticals BLCM	2.66 M	-	-9.72 %	$ 5.89 M	USA
BioMarin Pharmaceutical BMRN	15.3 M	$ 63.02	0.15 %	$ 12 B	USA
Baudax Bio BXRX	1.36 M	-	0.59 %	$ 63 K	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Amneal Pharmaceuticals AMRX	11.8 M	$ 14.72	2.08 %	$ 4.55 B	USA
Calithera Biosciences CALA	2.65 M	-	-10.95 %	$ 876 K	USA
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA